Journal article
Modelling antiviral treatment to prevent hepatitis C infection among people who inject drugs in Victoria, Australia
ME Hellard, R Jenkinson, P Higgs, MA Stoové, R Sacks-Davis, J Gold, M Hickman, P Vickerman, NK Martin
Medical Journal of Australia | Published : 2012
DOI: 10.5694/mja11.10981
Abstract
Objectives: To develop a mathematical model to project the potential impact of hepatitis C virus (HCV) treatment on HCV infection prevalence among people who inject drugs (PWID). Design and setting: An existing model of HCV transmission among PWID was parameterised using data from Victoria, Australia, including specific parameter estimates of the number of people who are currently active injecting drug users, average duration of injecting, chronic HCV infection prevalence among PWID, annual mortality, and annual HCV treatment rate. We also explored the impact of prevalence uncertainty, program scale-up, and new treatments. Main outcome measure: Prevalence of chronic HCV infection among peopl..
View full abstractGrants
Awarded by Medical Research Council
Funding Acknowledgements
Margaret Hellard was supported by a National Health and Medical Research Council (NHMRC) Research Fellowship. Rachel Sacks-Davis was supported by an NHMRC PhD scholarship. Peter Higgs was supported by an NHMRC Research Post Doctoral Fellowship. Natasha Martin was supported by Health Protection Scotland. Peter Vickerman was supported by the Medical Research Council, UK. Rebecca Jenkinson and Mark Stoove were supported by Centre for Research Excellence into Injecting Drug Use Fellowships.